Goldstein D J, Wilson M G, Thompson V L, Potvin J H, Rampey A H
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
Br J Psychiatry. 1995 May;166(5):660-6. doi: 10.1192/bjp.166.5.660.
A large collaborative 8-week study has shown fluoxetine to be effective and safe in treating patients with bulimia nervosa. The present study evaluated fluoxetine over 16 weeks.
Fifteen US out-patient psychiatry clinics conducted a double-blind parallel study in men and women with DSM-III-R bulimia nervosa (483 patients entered, 398 randomised [3:1 ratio, fluoxetine 60 mg/day or placebo], 225 completed). Outcome measures included change in vomiting and binge-eating episodes per week. Eating Disorder Inventory, Clinical Global Impressions and Patient's Global Impression.
Compared with placebo, fluoxetine treatment resulted in significantly greater reductions in vomiting (F[1,360] = 14.73, P < 0.0001) and binge-eating (F[1,360] = 14.39, P = 0.0002) episodes per week at endpoint and improvement in other outcome measures. Adverse event, vital sign and laboratory analyses indicated that fluoxetine was safe.
Fluoxetine appeared to be safe and effective in patients with bulimia nervosa for up to 16 weeks.
一项为期8周的大型合作研究表明，氟西汀在治疗神经性贪食症患者方面有效且安全。本研究对氟西汀进行了为期16周的评估。
15家美国门诊精神病诊所对患有DSM-III-R神经性贪食症的男性和女性进行了一项双盲平行研究（483名患者参与，398名随机分组[比例为3:1，氟西汀60毫克/天或安慰剂]，225名完成研究）。结果测量指标包括每周呕吐和暴饮暴食发作次数的变化、饮食失调量表、临床总体印象和患者总体印象。
与安慰剂相比，在研究终点时，氟西汀治疗使每周呕吐（F[1,360]=14.73，P<0.0001）和暴饮暴食（F[1,360]=14.39，P=0.0002）发作次数显著减少，其他结果测量指标也有所改善。不良事件、生命体征和实验室分析表明氟西汀是安全的。
氟西汀在神经性贪食症患者中长达16周似乎都是安全有效的。
